Engineering Bacteria and Their Derivatives for Cancer Immunotherapy

Overview

Journal BME Front

Specialty Biomedical Engineering

Date 2024 Aug 21

PMID 39165407

Authors

Yuji Tang

Chen Yu

Lang Rao

Affiliations

Soon will be listed here.

Abstract

Leveraging bacteria for cancer immunotherapy has gradually attracted wide attention since the discovery of "Cloey's toxin." However, one of the persistent challenges for bacteria-based therapy is striking a balance between safety and immunogenicity. Genetically engineered bacteria with virulence factors removed could further enhance antitumor ability by integrating genetic elements. In addition, bacterial derivatives, including outer membrane vesicles (OMVs) produced by bacterial secretion and nanovesicles synthesized by modification of OMVs, could enhance antitumor immunity while improving safety. This perspective discusses the unique advantages of engineered bacteria and their derivatives for immunotherapy, as well as the challenges that need to be overcome to achieve clinical translation.

References

Yue Y, Xu J, Li Y, Cheng K, Feng Q, Ma X . Antigen-bearing outer membrane vesicles as tumour vaccines produced in situ by ingested genetically engineered bacteria. Nat Biomed Eng. 2022; 6(7):898-909. DOI: 10.1038/s41551-022-00886-2. View

Liu L, Pan Y, Zhao C, Huang P, Chen X, Rao L . Boosting Checkpoint Immunotherapy with Biomaterials. ACS Nano. 2023; 17(4):3225-3258. DOI: 10.1021/acsnano.2c11691. View

Ma X, Liang X, Li Y, Feng Q, Cheng K, Ma N . Modular-designed engineered bacteria for precision tumor immunotherapy via spatiotemporal manipulation by magnetic field. Nat Commun. 2023; 14(1):1606. PMC: 10036336. DOI: 10.1038/s41467-023-37225-1. View

Zhao C, Pan Y, Yu G, Zhao X, Chen X, Rao L . Vesicular Antibodies: Shedding Light on Antibody Therapeutics with Cell Membrane Nanotechnology. Adv Mater. 2023; 35(12):e2207875. DOI: 10.1002/adma.202207875. View

Qing S, Lyu C, Zhu L, Pan C, Wang S, Li F . Biomineralized Bacterial Outer Membrane Vesicles Potentiate Safe and Efficient Tumor Microenvironment Reprogramming for Anticancer Therapy. Adv Mater. 2020; 32(47):e2002085. DOI: 10.1002/adma.202002085. View

Chowdhury S, Castro S, Coker C, Hinchliffe T, Arpaia N, Danino T . Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nat Med. 2019; 25(7):1057-1063. PMC: 6688650. DOI: 10.1038/s41591-019-0498-z. View

Chen L, Qin H, Zhao R, Zhao X, Lin L, Chen Y . Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines. Sci Transl Med. 2021; 13(601). DOI: 10.1126/scitranslmed.abc2816. View

Vanaja S, Russo A, Behl B, Banerjee I, Yankova M, Deshmukh S . Bacterial Outer Membrane Vesicles Mediate Cytosolic Localization of LPS and Caspase-11 Activation. Cell. 2016; 165(5):1106-1119. PMC: 4874922. DOI: 10.1016/j.cell.2016.04.015. View

Lamm D . BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology (Williston Park). 1995; 9(10):947-52, 955, discussion 955-65. View

10.

Kreitz J, Friedrich M, Guru A, Lash B, Saito M, Macrae R . Programmable protein delivery with a bacterial contractile injection system. Nature. 2023; 616(7956):357-364. PMC: 10097599. DOI: 10.1038/s41586-023-05870-7. View

11.

Feng Q, Ma X, Cheng K, Liu G, Li Y, Yue Y . Engineered Bacterial Outer Membrane Vesicles as Controllable Two-Way Adaptors to Activate Macrophage Phagocytosis for Improved Tumor Immunotherapy. Adv Mater. 2022; 34(40):e2206200. DOI: 10.1002/adma.202206200. View

12.

Qin H, Chen Y, Wang Z, Li N, Sun Q, Lin Y . Biosynthesized gold nanoparticles that activate Toll-like receptors and elicit localized light-converting hyperthermia for pleiotropic tumor immunoregulation. Nat Commun. 2023; 14(1):5178. PMC: 10449932. DOI: 10.1038/s41467-023-40851-4. View

13.

Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W . Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019; 178(4):795-806.e12. PMC: 7288240. DOI: 10.1016/j.cell.2019.07.008. View

14.

Zhang J, Wan S, Zhou H, Du J, Li Y, Zhu H . Programmed Nanocloak of Commensal Bacteria-Derived Nanovesicles Amplify Strong Immunoreactivity against Tumor Growth and Metastatic Progression. ACS Nano. 2024; 18(13):9613-9626. DOI: 10.1021/acsnano.3c13194. View

15.

Zheng D, Deng W, Song W, Wu C, Liu J, Hong S . Biomaterial-mediated modulation of oral microbiota synergizes with PD-1 blockade in mice with oral squamous cell carcinoma. Nat Biomed Eng. 2021; 6(1):32-43. DOI: 10.1038/s41551-021-00807-9. View

16.

Starnes C . Coley's toxins. Nature. 1992; 360(6399):23. DOI: 10.1038/360023b0. View

17.

Teufel L, Arts R, Netea M, Dinarello C, Joosten L . IL-1 family cytokines as drivers and inhibitors of trained immunity. Cytokine. 2021; 150:155773. DOI: 10.1016/j.cyto.2021.155773. View

18.

Liu G, Ma N, Cheng K, Feng Q, Ma X, Yue Y . Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity. Nat Nanotechnol. 2023; 19(3):387-398. DOI: 10.1038/s41565-023-01553-6. View

19.

Sylvester R . Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer. Int J Urol. 2010; 18(2):113-20. DOI: 10.1111/j.1442-2042.2010.02678.x. View

20.

Wang M, Rousseau B, Qiu K, Huang G, Zhang Y, Su H . Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses. Nat Biotechnol. 2023; 42(8):1263-1274. DOI: 10.1038/s41587-023-01957-8. View